Hepatitis C: Game changing regimens to revolutionise treatment landscape - KOL Insight
Approval of Gilead’s once daily oral nucleotide inhibitor Sovaldi marks a significant step in the treatment of hepatitis C (HCV). With efficacy over 90% in GT1/2/3/4 patients, this safe, best in class therapy represents a paradigm shift compared to the protease inhibitors and interferon regimens. With convenient, efficacious and safer therapies coming through the pipeline – led by Gilead, AbbVie and Bristol-Myers Squibb – the battle to transform this potentially lucrative market will be intense.
Therapy Trends: Hepatitis C is compiled from exclusive, in-depth interviews with the world’s leading KOLs in HCV. It identifies and analyses the major factors, advances and trends currently influencing the HCV treatment landscape. The report focuses on late-stage pipeline products and existing marketed therapies, providing strategic insights which key industry decision makers use to answer critical business questions.
FirstWord selected KOLs for this report based on their level of engagement and influence within the HCV pharmaceutical industry, and on their scientific standing. Our unique KOL scoring system identifies those thought-leaders with the greatest insight into how HCV clinical research will shape the future market.
Key Benefits
Therapy Trends: Hepatitis C -- Game changing regimens to revolutionise treatment landscape examines the most prominent insights gained from the field’s key opinion leaders.
The results of FirstWord’s research and analysis will help you to:
KOLs from North America and Europe provide answers to some critical questions regarding the global HCV market, including:
FirstWord selected the KOLs for this Therapy Trends report based on their level of engagement and influence within the HCV pharmaceutical industry, and their scientific standing.
The HCV KOL panel assembled for this Therapy Trends research is drawn from North America and Europe professionals:
Therapy Trends keeps you up to date with critical expert insight on the impact of market shaping events
FirstWord provides event-driven research update bulletins for 12 months following the purchase of Therapy Trends, thereby providing you with a continuously updated analysis service. FirstWord analysts constantly monitor the market and rapidly obtain the reactions of key opinion leaders following a significant event, such as a marketing approval or when the results of pivotal clinical trials are reported. This continuous monitoring and frequent engagement with experts provides timely access to the strategic insights which support critical business decisions.
Methodology
This report provides a qualitative overview of the current and future Hepatitis C (HCV) market. Information was gathered from telephone discussions held with twelve key opinion leaders (KOLs), from across the major HCV markets, including France, Germany, Italy, the UK and the US. These regions were selected because they contain many of the largest global markets for the pharmaceutical industry, and also influence the dynamics of Pharma markets in other countries.
In order to critically select Key Opinion Leaders (KOLs) a number of parameters were considered including their clinical experience, scientific publications, involvement with Pharma, involvement in clinical trials, and record of presenting at high profile international conferences.
Subject matter for discussion in the interviews covered future diagnostic and therapeutic strategies for HCV, the future of HCV drug classes, and new drugs entering the market. These leading KOLs also gave their views on current research, the usefulness of existing HCV drug classes, the cost of newer drugs and other concerns in the therapy area.
Therapy Trends: Hepatitis C is compiled from exclusive, in-depth interviews with the world’s leading KOLs in HCV. It identifies and analyses the major factors, advances and trends currently influencing the HCV treatment landscape. The report focuses on late-stage pipeline products and existing marketed therapies, providing strategic insights which key industry decision makers use to answer critical business questions.
FirstWord selected KOLs for this report based on their level of engagement and influence within the HCV pharmaceutical industry, and on their scientific standing. Our unique KOL scoring system identifies those thought-leaders with the greatest insight into how HCV clinical research will shape the future market.
Key Benefits
Therapy Trends: Hepatitis C -- Game changing regimens to revolutionise treatment landscape examines the most prominent insights gained from the field’s key opinion leaders.
The results of FirstWord’s research and analysis will help you to:
- Comprehend the current trends driving and shaping the global HCV market
- Assess the commercial and clinical potential of the pipeline nucs, non-nucs, NS5A inhibitors and next generation protease inhibitors
- Develop planning strategies based on KOL insight
- Identify the unmet needs and opportunities for disease management
- Evaluate the performance of companies with the most robust new product pipelines
- Recognise the key factors KOLs predict will drive future treatment trends
KOLs from North America and Europe provide answers to some critical questions regarding the global HCV market, including:
- What do KOLs make of the Sovaldi and Olysio and their impact on treatment?
- What are the current unmet needs and major challenges in HCV treatment?
- What are the most promising late-stage classes in development?
- Which therapies are KOLs eagerly awaiting?
- How will the nucleotide inhibitors, non-nucs, and NS5A inhibitors be positioned in the HCV market?
- How do the second generation protease inhibitors differ from their first-generation cousins?
- In what ways could eventual biomarkers improve future HCV disease management?
- How will treatment of HCV look in the future?
- How do KOLs think the pricing of new direct-acting antivirals will shape the uptake of new HCV treatments?
- What clinical research trends do KOLs predict for future HCV therapies?
FirstWord selected the KOLs for this Therapy Trends report based on their level of engagement and influence within the HCV pharmaceutical industry, and their scientific standing.
The HCV KOL panel assembled for this Therapy Trends research is drawn from North America and Europe professionals:
- Adult Viral Hepatitis Prevention Coordinator, Bureau of Epidemiology, Pennsylvania Department of Health, Harrisburg, PA, USA
- Director of Hepatology, Medicine Service, Massachusetts General Hospital, MA, USA
- President and Medical Director at Alamo Medical Research, Texas, USA
- Head, Division of Gastroenterology and Hepatology, Scripps Clinic, CA, USA
- Chief Medical Officer at Alamo Medical Research Texas, USA
- Head of the Liver Institute of Virginia, Virginia, USA
- Department of Hépato-Gastroenterologie, Centre Hospitalier Universitaire de Nancy-Brabois, Vandoeuvre-lès-Nancy, France
- Professor of Medicine at the University of Vienna, Vienna General Hospital, Wien, Austria
- Professor at Hôpital Saint Eloi, Montpellier, France
- Co-lead of HCV Research UK, MRC Virology Unit, Glasgow, Scotland
- Professor of Medicine and Chief of the Department of Medicine, J.W. Goethe University Hospital, Frankfurt, Germany
Therapy Trends keeps you up to date with critical expert insight on the impact of market shaping events
FirstWord provides event-driven research update bulletins for 12 months following the purchase of Therapy Trends, thereby providing you with a continuously updated analysis service. FirstWord analysts constantly monitor the market and rapidly obtain the reactions of key opinion leaders following a significant event, such as a marketing approval or when the results of pivotal clinical trials are reported. This continuous monitoring and frequent engagement with experts provides timely access to the strategic insights which support critical business decisions.
Methodology
This report provides a qualitative overview of the current and future Hepatitis C (HCV) market. Information was gathered from telephone discussions held with twelve key opinion leaders (KOLs), from across the major HCV markets, including France, Germany, Italy, the UK and the US. These regions were selected because they contain many of the largest global markets for the pharmaceutical industry, and also influence the dynamics of Pharma markets in other countries.
In order to critically select Key Opinion Leaders (KOLs) a number of parameters were considered including their clinical experience, scientific publications, involvement with Pharma, involvement in clinical trials, and record of presenting at high profile international conferences.
Subject matter for discussion in the interviews covered future diagnostic and therapeutic strategies for HCV, the future of HCV drug classes, and new drugs entering the market. These leading KOLs also gave their views on current research, the usefulness of existing HCV drug classes, the cost of newer drugs and other concerns in the therapy area.
1.CURRENT HEPATITIS C MARKETPLACE
1.1.Hepatitis C overview
1.2.Current treatment landscape
1.3.Reimbursement of key Hepatitis C brands
1.4.Unmet needs in Hepatitis C
2.CURRENT THERAPIES
2.1.NS5B nucleoside (Nuc) inhibitors overview
2.1.1.1Sovaldi (sofosbuvir; Gilead Sciences) trends
2.3.NS3/NS4A Protease inhibitor overview
2.3.1.Olysio (simeprevir; Medivir/Janssen) trends
2.3.2.Incivek/Incivo (telaprevir; Vertex's/ Janssen/Mitsubishi Tanabe) trends
2.3.3.Victrelis (boceprevir; Merck) trends
2.4.Interferon and Ribavirin Overview
2.4.1.Pegylated interferon-alpha (Peg-Intron, PegaSys) and ribavirin trends
2.5.Current treatment algorithm
3.FUTURE HEPATITIS C MARKETPLACE
3.1.Future treatment landscape
3.2.NS5B nucleoside (Nuc) inhibitors overview
3.2.1.Mericitabine (RO5024048; Roche/Gilead) trends
3.3.NS5B non-nucleoside inhibitor overview
3.3.1.ABT-333 (AbbVie) trends
3.3.2.ABT-072 (AbbVie) trends
3.3.3.VX-222 (Vertex) trends
3.3.4.Tegobuvir (GS-9190; Gilead) trends
3.4.NS5A replication complex inhibitor overview
3.4.1.Daclatasvir (BMS-790052; Bristol-Myers Squibb) trends
3.4.2.GS-5885 (Gilead Sciences) trends
3.4.3.ABT-267 (AbbVie) trends
3.4.4.ACH-3102 (Achillion) trends
3.5.NS3/NS4A protease inhibitor overview
3.5.1.Faldaprevir (BI-201335; Boehringer Ingelheim) trends
3.5.2.ABT-450 (AbbVie/Enanta) trends
3.5.3.Asunaprevir (BMS-650032; Bristol-Myers Squibb) trends
3.5.4.Danoprevir (RO5190591; Roche) trends
3.5.5.Sovaprevir (ACH-1625; Achillion Pharmaceuticals) trends
3.5.6.MK-5172 (Merck) trends
3.6.Future treatment algorithm
4.FUTURE DEVELOPMENTS IN HEPATITIS C
4.1.Education to raise awareness and improve diagnosis
4.2.Clinical trials will evolve in the future
4.4.Constrained pricing environments will reduce market access
4.5.Effective shorter treatment regimes will emerge
4.6.biomarkers will be useful but not essential
1.1.Hepatitis C overview
1.2.Current treatment landscape
1.3.Reimbursement of key Hepatitis C brands
1.4.Unmet needs in Hepatitis C
2.CURRENT THERAPIES
2.1.NS5B nucleoside (Nuc) inhibitors overview
2.1.1.1Sovaldi (sofosbuvir; Gilead Sciences) trends
2.3.NS3/NS4A Protease inhibitor overview
2.3.1.Olysio (simeprevir; Medivir/Janssen) trends
2.3.2.Incivek/Incivo (telaprevir; Vertex's/ Janssen/Mitsubishi Tanabe) trends
2.3.3.Victrelis (boceprevir; Merck) trends
2.4.Interferon and Ribavirin Overview
2.4.1.Pegylated interferon-alpha (Peg-Intron, PegaSys) and ribavirin trends
2.5.Current treatment algorithm
3.FUTURE HEPATITIS C MARKETPLACE
3.1.Future treatment landscape
3.2.NS5B nucleoside (Nuc) inhibitors overview
3.2.1.Mericitabine (RO5024048; Roche/Gilead) trends
3.3.NS5B non-nucleoside inhibitor overview
3.3.1.ABT-333 (AbbVie) trends
3.3.2.ABT-072 (AbbVie) trends
3.3.3.VX-222 (Vertex) trends
3.3.4.Tegobuvir (GS-9190; Gilead) trends
3.4.NS5A replication complex inhibitor overview
3.4.1.Daclatasvir (BMS-790052; Bristol-Myers Squibb) trends
3.4.2.GS-5885 (Gilead Sciences) trends
3.4.3.ABT-267 (AbbVie) trends
3.4.4.ACH-3102 (Achillion) trends
3.5.NS3/NS4A protease inhibitor overview
3.5.1.Faldaprevir (BI-201335; Boehringer Ingelheim) trends
3.5.2.ABT-450 (AbbVie/Enanta) trends
3.5.3.Asunaprevir (BMS-650032; Bristol-Myers Squibb) trends
3.5.4.Danoprevir (RO5190591; Roche) trends
3.5.5.Sovaprevir (ACH-1625; Achillion Pharmaceuticals) trends
3.5.6.MK-5172 (Merck) trends
3.6.Future treatment algorithm
4.FUTURE DEVELOPMENTS IN HEPATITIS C
4.1.Education to raise awareness and improve diagnosis
4.2.Clinical trials will evolve in the future
4.4.Constrained pricing environments will reduce market access
4.5.Effective shorter treatment regimes will emerge
4.6.biomarkers will be useful but not essential
